Jefferies Cuts PT on ARIAD Pharma (ARIA) Due to Iclusig Safety Issues, Maintains Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ARIAD Pharma (ARIA) Receives Accelerated FDA Approval for Iclusig as CML Treatment
December 14, 2012 12:48 PM ESTARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI... More
Ariad Pharmaceuticals (ARIA) Moves Higher after FDA Node for Iclusig
December 14, 2012 11:51 AM ESTAriad Pharmaceuticals, Inc. (NASDAQ: ARIA) moves higher on news the FDA approved Iclusig to treat two rare types leukemia.... More
